Rebirth: I don’t want to be a leek anymore

The next day, Su Zhe began meeting with some executives of international investment banks in China.

Goldman Sachs, JPMorgan Chase, Citibank, Sequoia Capital and other international investment banks heard that Jiushen Group was going to carry out international stock investment business, and they rushed to negotiate.

These well-informed large companies have long known the strength of Su Zhe and the Jiushen Group.

This is a big customer, whether it is foreign exchange business, financing business, or short business, they can do agency services for Jiushen.

They are in the United States and have strong resources, no matter which stock Su Zhe wants to short, they can find relevant banks and lend out the stocks that are pledged in the bank.

In order to prevent being sniped, Su Zhe decided to cooperate and not let one company grasp all his investment operations.

Although Su Zhe doesn't know much about the situation of U.S. stocks in 18 years. But he still knows the ups and downs of some industries, as well as large companies.

For example, Amazon, which rose very well in 18, and Microsoft also rose.

And the plate of these two people's company is very large, billions of dollars are scattered in a few days, and there is no splash at all.

Tesla, on the other hand, only began to rise in mid-19, and it is not in a hurry now.

Three days later, Jiushen Group began to take out loans.

That's right, it's a loan.

I heard that Jiushen Group was going to take out a loan, and the four major domestic banks and various commercial banks came to the door together, and Zhao Pengyuan was responsible for entertaining and docking.

The first wave of banks screened by Zhao Pengyuan were those with a credit of less than 5 billion yuan, and they were directly out.

The second wave, those who need a mortgage, go back and think about it clearly, and then come back, if you need a mortgage, will it be your turn?

When international investment banks heard the news, they came to Jiushen Group one after another.

They don't need a mortgage, they only need Su Zhe to bear joint and several guarantee liability.

You must know that Su Zhe's assets and short orders on the other side of the exchange have increased in value every day over time.

The credit lines offered by these investment banks start at $1 billion.

Su Zhe and Jiushen Group do not have any non-performing assets, no debt ratio, only a large amount of cash and high-quality assets such as byte shares, holding a telescope, You won't even be able to find a second customer with such a good loan.

Zhao Pengyuan got a total credit of 20 billion US dollars in half a month, with an average annual interest rate of 5.5%, and when to use it and when to start calculating interest.

This cost of capital is relatively low, the main reason is that the assets of Jiushen Group are too high-quality, and there is no company in the world with assets of hundreds of billions and a debt ratio of 0.

That's why the total credit exceeds the total assets of Jiushen. However, even if it is fully lent out, the debt ratio of Jiushen Group is about 60%, and most of the assets are cash and equivalents, which is also very healthy.

In the past half a month, the new human resources director has arrived, and the framework of the international stock trading department has been formed.

On this night, Su Zhe personally sat in the newly listed international stock trading department.

In front of you is a row of traders, staring at their computers, waiting for the market to open.

Su Zhe crossed his waist, like a warrior about to go on a journey.

He seems to have regained the feeling of fighting last year's day and night speculation.

Beside him, stood Li Hezhen, Ye Mengquan and You Haida.

There is also a logistics support department outside, which is responsible for taking care of this department.

I started work at night, and after the U.S. stock market closed at 3 a.m., the review meeting lasted for one to two hours, and when I got off work, it was almost dawn.

"Mr. Su, it's open."

"Okay, now start eating Amazon, Microsoft, Twitter stocks, be careful not to cause price fluctuations, I'm not in a hurry."

"Yes, Mr. Su."

After Su Zhe finished speaking, he sat down in his chair and began to frown, looking at the analyst's report. In this new department, Su Zhe spent a lot of money, not only all traders are five years of experience as U.S. stock traders, but also recruited two senior Wall Street stock analysts, and according to their requirements, equipped with the entire analysis team.

This is the first U.S. stock analysis report they submitted to Su Zhe.

Su Zhe has no system, and he doesn't have a superhuman memory, but in his previous life, he would look at stock posts or news every year, which was an interest.

So he saw it, but forgot about it. But if he sees the names of those stocks that have risen again, there is a high probability that it will awaken his memory.

Especially the demon stocks every year, or the stocks that have fallen very badly, these companies on the list, as long as they see it again, Su Zhe will definitely be able to think about it.

The first page of this analysis is about medicine, because one of the analysts used to analyze the field of medicine. In the report, he mentioned that he is very optimistic about a multinational pharmaceutical group called Pfizer.

This name is so familiar, don't say whether it can rise this year, thinking of this company that will sell all over the world in the future, Su Zhe decided to buy it with his eyes closed.

However, seeing Pfizer, Su Zhe suddenly thought that after reading the post before, among the 30 constituent stocks of Dow Jones in 18 years, the best performer was the world's pharmaceutical giants??? , the second place turned out to be the pharmaceutical stock Pfizer.

When he saw Pfizer, he thought of this memory, Pfizer was not the most rising Dow Jones constituent stock in 18 years, and the first place was also a pharmaceutical giant.

For Su Zhe, he will not operate any small-cap stocks, which will not contain a lot of his funds, so his target is the constituent stocks of the three major U.S. stock exchanges.

But he couldn't remember for a while, which company it was, and he hurriedly ordered: "Sort out the pharmaceutical stocks in the Dow Jones constituent stocks, I want to look at them, and in addition, give me Pfizer." "

Yes!"

Soon, a piece of paper was delivered to Su Zhe, and a list of Chinese and English lists was all Dow Jones' pharmaceutical constituents.

Su Zhe picked it up, read it all, and then looked at it again, and he suddenly had a flash of inspiration and locked on the name Merck. Because when he saw the name of this company, he wondered if this was a Middle Eastern company? After all, there are a lot of names in the Middle East, and the words "sand" and "east" are very relevant to the Middle East.

But he couldn't be 100% sure, so he asked, "Is this Merck a pharmaceutical giant?" "

The analyst said: 'Merck & Co., Ltd., a company based in Kenilworth, New Jersey, USA, in 2016, Merck & Co., Ltd. had global sales of $50 billion and R&D investment of $6.5 billion, and last year's earnings report has not yet been released. They have tens of thousands of employees around the world, and Merck & Co., Ltd. is headquartered in Modu in China, and in the 2017 Fortune 500 list in the United States, Merck & Co., Inc. ranked 69th, and in the Fortune Global 500 list, Merck ranked 276th. It is a global pharmaceutical giant.

After listening, Su Zhe finally determined that this was the thing.

With a big wave of his hand.

"Buy it!"